Finding accredited CPD
Warfarin (vitamin K antagonist) remains an established anticoagulant for patients at high risk of arterial and venous thromboembolism. The prompt reversal of the anticoagulant effect of warfarin is necessary in the context of major bleeding or emergency surgery because of its extended inhibition of vitamin K‐dependent coagulation factors for days. The mainstay of urgent warfarin reversal has been vitamin K administration, and infusion of a three‐factor prothrombin complex concentrate (3FPCC) and the option for the addition of fresh frozen plasma as a source of factor VII. With the upcoming introduction in Australia and New Zealand of a four‐factor prothrombin complex concentrate (4FPCC), which replaces all the vitamin K‐dependent clotting factors, this article updates the previously published warfarin reversal guidelines.
This MJA Position Statement shares more.
Authors: Danielle Robinson, James McFadyen, Eileen Merriman, Chee Wee Tan, Ross Baker and Huyen Tran
Article Type: Position Statement
*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)
